Most of the squamous cell carcinomas (SCCs) of the skin and head and neck contain p53 mutations. The presence of p53 mutations in premalignant lesions suggests that they represent early events during tumor progression and additional alterations may be required for SCC development. Here we show that codeletion of the p53 and av integrin genes in mouse stratified epithelia induced SCCs in 100% of the mice, more frequently and with much shorter latency than deletion of either gene alone. The SCCs that lacked p53 and av in the epithelial tumor cells exhibited high Akt activity, lacked multiple types of infiltrating immune cells, contained a defective vasculature and grew slower than tumors that expressed p53 or av. These results reveal that loss of av in epithelial cells that lack p53 promotes SCC development, but also prevents remodeling of the tumor microenvironment and delays tumor growth. We observed that Akt inactivation in SCC cells that lack p53 and av promoted anoikis. Thus, tumors may arise in these mice as a result of the increased cell survival induced by Akt activation triggered by loss of av and p53, and by the defective recruitment of immune cells to these tumors, which may allow immune evasion. However, the defective vasculature and lack of a supportive stroma create a restrictive microenvironment in these SCCs that slows their growth. These mechanisms may underlie the rapid onset and slow growth of SCCs that lack p53 and av.
INTRODUCTION
Squamous cell carcinomas (SCCs) are malignant tumors that arise from the keratinocytes that form the stratified epithelial lining of the body, including the skin and the oral mucosa. Although SCCs represent less than one-third of the non-melanoma skin cancers diagnosed, they are responsible for most of the non-melanoma skin cancer-related deaths. 1 Also, SCC is the most common skin cancer in immunosuppressed organ transplant recipients, and the SCC risk is 65-250 times higher in this population than in the general population, suggesting that immune surveillance mechanisms protect against SCC development.
2,3
The p53 gene is the most frequently mutated gene in skin and head and neck SCCs, with p53 mutations present in over 50% of the human SCCs diagnosed. [4] [5] [6] Mutations in p53 are also found in premalignant lesions that are considered SCC precursors, suggesting that p53 mutation is an early event that precedes progression to carcinoma. 7, 8 Indeed, patches of epidermal cells with p53 mutations have been observed in sun-exposed skin, although SCCs usually appear decades after p53 mutations are detected. 9, 10 Similarly, mice with conditional deletion of p53 in the skin developed SCCs after very long latency periods, indicating that additional molecular or cellular alterations are needed to promote SCC development. [11] [12] [13] The epithelial organization in the epidermis is maintained largely by the molecular adhesions that connect keratinocytes with adjacent cells and the underlying basement membrane. The integrin family has a critical role in mediating cell adhesion and facilitating communication between keratinocytes and surrounding cells as well as with components of the stroma; 14 they are also involved in cell proliferation, survival, differentiation, migration and in cytoskeletal organization. 15 Integrins are a family of heterodimeric transmembrane proteins, each composed of an a-subunit and a b-subunit. The most highly expressed integrins in human and murine epidermis are a6b4, which is a component of the hemidesmosomes that mediate adhesion to laminin-332 in the basement membrane, and b1-integrins (primarily a2b1 and a3b1), which are expressed in cell clusters in epidermal basal cells and hair follicles; 16, 17 av integrins are detected at lower levels in the skin. The av subunit forms heterodimeric complexes with b1, b3, b5, b6 and b8. In the skin and oral mucosa, the primary integrins containing av units are avb5, which is expressed at low levels, and avb6, which is not detected in the intact skin but is induced in the skin during wound healing. 18, 19 The expression of integrins such as av is altered in human SCCs, resulting in complex, dynamic expression patterns. 20 A switch from avb5 expression to avb6 is frequently observed in human SCCs, and av expression tends to be higher in the less differentiated areas of these tumors. [21] [22] [23] In mice, conditional deletion of av using a transgene expressing Cre under the control of the glial fibrillary acid protein (GFAP) promoter induced epithelial tumors arising from the conjunctiva, 24 suggesting that av has a tumor suppressor role in the periorbital epithelium. However, the GFAP-Cre line used in these studies was expressed only in the developing epithelium of the eyelid, raising the question of whether the eyelid epithelium is highly susceptible to cancer in the setting of av deletion or whether av has a general tumor suppressor role in stratified epithelia.
To investigate how loss of av affects the development of SCCs of the skin and head and neck area, we deleted the av gene in stratified epithelia, including the epidermis and oral mucosa. Because most of the human SCCs carry mutations in p53, we examined the potential tumor suppressor role of av in epithelial cells in which the p53 gene was also deleted.
RESULTS
Loss of p53 and av integrin cooperate to induce skin and oral SCCs To determine the consequences of deleting the av integrin gene (Itgav) in stratified epithelia, we crossed mice carrying floxed alleles for av (av f ) with K14.CrePR1 transgenic mice, which express a Cre recombinase that can be activated in stratified epithelia upon exposure to RU486. 25, 26 Leaky Cre activity in K14.CrePR1 mice also allows activation of conditional alleles in a subset of cells in the epidermis and in the mucosa of the oral and anorectal epithelia. 26 As p53 is the major tumor suppressor gene in human cutaneous and oral SCCs, we were interested in assessing whether loss of av modulates the tumor suppressor function of p53 in the epidermis and oral mucosa. Thus, we crossed the av f mice with floxed p53 mice (p53 f ) 11 and generated mice carrying homozygous or heterozygous combinations of av f and p53 f alleles in the presence of K14.CrePR1. To maximize Cre activation in the epidermis, newborn mice received a daily topical application of RU486 (1 mg/ml) for 3 days. Surprisingly, only 2 of 26 mice with homozygous deletion of av (av f/f -p53 wt/wt mice) developed SCCs by 24 months of age. This low tumor incidence may be explained by the induction of p53 in emerging tumors that lost av (Supplementary Figure S1) . The incidence of SCC in these mice was significantly lower than that observed in mice with homozygous deletion of p53 alone (av wt/wt -p53 f/f ), half of which developed SCCs by 20 months of age. Nevertheless, SCCs developed with long latencies in both av f/f -p53 wt/wt and av wt/wt -p53 f/f mice, suggesting that although deletion of either av or p53 predispose to SCC, additional genetic and/or molecular barriers prevent SCC development. Remarkably, mice in which both copies of the p53 and av genes were codeleted (av f/f -p53 f/f ) developed SCCs with an average latency of only 6-7 months and 100% penetrance (Figure 1a) . The tumor latency increased in the presence of a wild-type (wt) allele for either av or p53, and tumors appeared slightly faster in av f/f -p53 f/wt mice (14-15 months) than in av f/wt -p53 f/f mice (16-17 months). Notably, only five of the mice studied developed metastasis (1 av f/f -p53 f/f mouse, 2 av f/f -p53 f/wt mice and 2 av f/wt -p53 f/f mice). Overall, these findings indicate that loss of p53 and av cooperate to induce SCC development. Because p53 mutations are found in most of the human SCCs, these observations suggest that loss of av facilitates SCC development from epithelial cells that accumulate mutations in p53.
Distinct phenotypic variants in SCCs induced by codeletion of p53 and av Most of the av f/f -p53 f/f mice (92%) developed skin tumors, and a significant number of these mice also developed tumors in the head and neck (17%), the anorectal epithelia (14%) and the periorbital area (6%) (Figure 1b and Supplementary Table S1 ). This distribution of tumor locations was similar to that in mice with other genotypes analyzed in this study, although the incidence of oral tumors was slightly higher in av f/f -p53 f/wt mice (28%).
Histologically, most of the tumors that developed in the av f/f -p53 f/f mice (hereafter referred to as av À /p53 À tumors) were invasive SCCs, with a spectrum of phenotypic variants. Over onethird of the av À /p53 À SCCs comprised nests of tumor cells organized in pseudoglandular formations enclosing terminally differentiated keratinocytes (Figure 1c) . In some tumors, these intraluminal cells were lost as a result of acantholysis (Figure 1d) , and other tumors exhibited extensive areas devoid of cells, with no apparent pseudoglandular formations surrounding the empty spaces, suggesting complete degeneration (Figure 1e ). Collectively, these phenotypes represent histologic variants of pseudoglandular or acantholytic SCCs. 27 Of the av À /p53 À tumors, approximately 30% were conventional, well-to moderately differentiated SCCs (Figure 1f ), whereas o10% of the tumors were poorly differentiated SCCs that occasionally exhibited areas with marked epithelial-mesenchymal transition (EMT) (not shown).
Interestingly À tumors exhibiting such phenotype. Taken together, these results indicate that loss of both p53 and av integrin induced the development of SCCs that tend to display pseudoglandular or acantholytic features, a phenotype promoted primarily by the loss of av. To assess potential changes in the expression of other a integrins after deletion of av, we analyzed the expression of a6 in SCCs (Supplementary Figure S2) . As expected, a6 localized to the basal surface of the basal cells in the epithelial component of av þ /p53 À conventional SCCs. A similar expression pattern was observed in pseudoglandular/acantholytic av À /p53 À SCCs, indicating that the loss of av did not impair the expression and localization of a6. The other two a integrins expressed in stratified epithelia (a2 and a3) showed much lower expression and a diffuse pattern in both av þ /p53 À and av À / p53 À SCCs (not shown).
Activation of Akt and Erk pathways in SCCs that lack p53 and av
In addition to their fundamental role in mediating cell-cell and cell-substrate adhesion, integrins can regulate signaling pathways that contribute to their pleiotropic effects during tissue homeostasis and disease. 15 Specifically, av integrins can bind to and modulate the activity of cell surface receptors, including growth factor receptor tyrosine kinases. 28 Notably, analysis of the phosphorylation levels of Akt and Erk revealed little to no activation of these pathways in av þ /p53 À SCCs, moderate activation in av À /p53 þ SCCs and a much stronger activation in av À /p53 À SCCs (Figure 2a and Supplementary Figure S3 ). Phosphorylation of Akt and Erk in the epithelial cells of the av À /p53 À tumors was confirmed by immunohistochemical analysis (Figures 2b and c) . Thus, the loss of both p53 and av promoted the synergistic activation of Akt and Erk in SCCs. Interestingly, Akt was shown to protect human SCC cells from detachment-induced cell death (anoikis). 29 We also found that Akt activity prevents anoikis in cells derived from an av À /p53 À SCC (Supplementary Figure S4) , suggesting that activation of Akt induced by the loss of p53 and av promotes cell survival during SCC development.
av Integrins can also promote transforming growth factor (TGF)-b signaling by inducing the dissociation of the latencyassociated peptide from the latency-associated peptide-TGF-b p53 and av cooperate during SCC development A Savar et al complex that maintains TGF-b in an inactive form. 30 Because TGF-b inhibits keratinocyte growth, it was speculated that av integrins may protect against squamous tumorigenesis by promoting TGF-b activation. 24 To evaluate the activation status of the TGF-b pathway in av À /p53 À tumors, we analyzed phosphorylation of Smad2 and Smad3, the primary mediators of TGF-b signaling. We detected phosphorylated (p) Smad2 and/or Smad3 in most of the SCCs analyzed, including av À /p53 À tumors, with slight variation between tumors of all genotypes (Figure 2a and Supplementary Figure S3 ). Because TGF-b can also induce proliferation of stromal fibroblasts, we decided to identify the tumor cell types that showed activated Smad. Immunohistochemical analysis of the SCCs revealed strong nuclear staining for p-Smad2 primarily in the epithelial tumor cells (Figure 2d ). These findings suggest that inactivation of the TGF-b pathway is not a major mechanism that accelerates the development of av À /p53 À SCCs. Similarly, activation of STAT3, which can be mediated by a wide variety of cytokines commonly found in tumors, was observed in most of the tumors we studied. (Figures 3a and b) .
We analyzed in more detail the nature of the infiltrating cells in SCCs by staining the tumors with antibodies for molecular markers of lymphocytes (CD3), neutrophils (Gr-1), macrophages (F4/80) and natural killer cells (Nk1.1). The numbers of CD3 þ cells in av þ / p53 À and av À /p53 þ tumors were similar and both significantly higher than those in av À /p53 À SCCs (Figures 3c and d) . Staining for Gr-1 revealed high levels of neutrophils in av þ /p53 À and av À /p53 þ tumors but not in av À /p53 À SCCs (Figures 3e and f) ; the number of Gr-1 þ cells varied among av þ /p53 À tumors and among av À /p53 þ tumors, with an elevated number of neutrophils in some tumors and almost none detected in others. Similarly, macrophages were detected in variable amounts in both av þ /p53 À and av À /p53 þ SCCs but were not found in av À /p53 À SCCs (Figures 3g and h) . Notably, the presence of neutrophils and macrophages was inversely correlated in most av þ /p53 À and av À /p53 þ SCCs; tumors with high levels of neutrophils tended to have few macrophages, and vice versa. Finally, we observed a lack of natural killer cells in av À /p53 À SCCs but not in tumors that expressed either av or p53 (Figures 3i and j) .
These findings prompted us to analyze other components of the stroma. This analysis revealed that CAFs, identified by the expression of a-smooth muscle actin (a À SMA), were present in tumors of all genotypes, although at significantly lower levels in av À /p53 À tumors than in av þ /p53 À and av À /p53 þ tumors (Figures 4a and b) . In addition, a detailed examination of the tumor vasculature identified the presence of endothelial cells in tumors of all genotypes. However, whereas av þ /p53 À and av À / p53
þ SCCs contained well-organized microvessels with defined lumens, the vasculature of av À /p53 À tumors consisted primarily of endothelial cells that lacked defined luminal formations (Figure 4c) . Indeed, quantification of the area encompassed by vascular cells revealed that microvessels in the av À /p53 À tumors covered a significantly smaller area of the tumor than those in av þ /p53 À and av À /p53 þ tumors (Figure 4d ). These observations indicate that SCCs that lack epithelial av and p53 contain a distinctive tumor microenvironment characterized by reduced levels of CAFs, a defective tumor vasculature, and a nearly complete absence of infiltrating immune cells.
Lack p53 and av in epithelial tumor cells delays tumor growth The cellular content and architecture of the stroma of av À /p53 À SCCs suggest that these tumors contain a restrictive microenvironment, most evidenced by the defective organization of the tumor vasculature, which may compromise the nutrient supply in these tumors. Indeed, we found that p16, a tumor suppressor induced under multiple stress conditions including nutrient deprivation, was highly expressed in the epithelial cells of the av À /p53 À tumors but not in av þ /p53 À and av À /p53 þ tumors (Figures 5a and c) . Remarkably, the elevated expression of p16 in av À /p53 À tumors was accompanied by a significant reduction in expression of the proliferation marker Ki-67, suggesting a slower cell growth in tumors induced by deletion of the av and p53 genes in epithelial cells (Figures 5b and d) . These observations prompted us to perform an exhaustive review of the rates of tumor growth in the mice generated in this study. Notably, we found that the av À /p53 À tumors took almost two times as long (Figure 5e ), indicating that despite the more rapid SCC development induced by codeletion of p53 and av in keratinocytes, subsequent tumor growth was compromised in the absence of both p53 and av.
Overall, these observations indicate that loss of av expression in epithelial cells that acquire p53 mutations allows the rapid development of SCCs. However, as the tumors progress, loss of av hinders tumor growth. This may explain why mutations in av are not found in human SCCs; a transient loss of av may suffice to allow SCC development and, as the tumor grow, reactivation of av may promote tumor growth. This analysis was consistent with the decreased expression of av observed in papillomas that were induced in the mouse skin by activation of oncogenic K-ras and mutant p53 in a previously generated mouse model for skin cancer progression 12, 32 (Supplementary Figure S5) . Interestingly, the expression of av increased in SCCs that developed in those mice and was highest in spindle cell carcinomas, the most aggressive tumors that developed in this model.
DISCUSSION
In this study, we generated mouse models that allowed us to demonstrate that loss of p53 and av integrin cooperate during the development of SCCs of the skin and the head and neck area. The high Akt activity observed in tumors that lack p53 and av suggests that resistance to anoikis promoted by Akt allows survival of keratinocytes that detach from their natural substrate and facilitate their growth into emerging tumors. Unlike SCCs that contained wt alleles for either p53 or av, the tumor microenvironment of SCCs induced by codeletion of p53 and av in keratinocytes was characterized by a defective vasculature and lack of both infiltrating immune cells and CAFs. The impaired recruitment of antitumor immune cells may facilitate immune evasion of emerging tumors, which contributes to the accelerated tumor formation. The defective vasculature and lack of tumorpromoting stromal cells may be responsible for the slow growth of tumors that lacked p53 and av. Thus, these mouse models represent an in vivo system in which genetic changes that accumulate in the epithelial cells determine not only the cellautonomous mechanisms that allow expansion of tumor cells but also the organization of the surrounding stroma, with a profound impact in tumor development and progression.
The low incidence of SCCs observed upon deletion of av by K14.CrePR1 suggested that epithelial cells targeted by GFAP-Cre and K14.CrePR1 are differently predisposed to SCC induced by deletion of av. As we found that the additional loss of p53 increased markedly the SCC rates, the higher tumor incidence observed when av was deleted by GFAP-Cre may result from the GFAP expression in precursor cells of the eyelid epithelium that have lower p53 activity, as has been observed in embryonic stem cells. 33, 34 Moreover, av can inactivate the p53 function in certain cell types, including human melanoma cells, 35, 36 suggesting that the p53 and av interaction may affect a broader spectrum of tumor types.
Mutations in p53 are found in most of the human SCCs. However, av mutations have not been reported in human SCCs. We propose that the transient or epigenetic inactivation of av in keratinocytes that accumulate p53 mutations facilitates SCC formation, which may have profound implications for the dynamics of SCC development because p53 mutations are frequently found in sun-exposed skin. 7, 8 However, tumors rarely develop from those cells. Our findings suggest that the loss of av expression in p53-mutant keratinocytes may trigger SCC development. However, as tumors grow, the lack of p53 and av in the epithelial tumor cells blocks the remodeling of the tumor microenvironment that promotes tumor growth. Thus, a reactivation of av in established tumors would facilitate tumor Figure S5) and in humans, where high levels of av were found in the leading front of SCCs. 23 Notably, a switch from avb5 to avb6 occurs during SCC development, 20, 29 as avb5 is expressed in the normal epidermis, but is lost during SCC progression; conversely, avb6 is not detected in the epidermis, but is upregulated in SCCs. In light of these dynamic changes in the expression of av integrins, the contrasting phenotypes that we observed after deletion of av in the skin (promoting SCC development, but suppressing tumor growth) may result from the opposing functions of avb5 and avb6, as avb5 may function as a tumor suppressor, whereas avb6 may be oncogenic. Because av deletion eliminates both avb5 and avb6, loss of avb5 may facilitate SCC formation, whereas the lack of avb6 in these tumors may prevent tumor growth. These mechanisms are compatible with changes in the expression of av during SCC progression discussed above, and it is possible that they operate together during SCC development.
It has been reported that the human SCC cells H357, which lack av and contain a p53 mutation, were resistant to anoikis. 37 Restoring av in these cells blocked Akt activation and induced anoikis, and expression of a constitutively active Akt suppressed anoikis, suggesting that av induced anoikis by blocking Akt activation; however, the role of p53 in this model was not tested. 29 Our data indicate that Akt activity was much higher in av À /p53 À SCCs than in tumors that expressed either p53 or av, and that blockade of Akt activity in av À /p53 À SCC cells promotes anoikis. Collectively, these observations suggest that the loss of av facilitates survival of p53-mutant epithelial cells that detach from the epithelial basement membrane, due to the high Akt activity promoted by the loss of av in the absence of p53. Thus, inhibition of anoikis seems to be an early step of SCC development in our model. Importantly, our data suggest that blockade of the Akt pathway in combination with av integrin inhibitors may be used to treat patients with SCCs that carry p53 mutations and to prevent tumor growth.
The evolution of solid tumors is not only determined by the genetic component of the epithelial tumor cells but also by the dynamic interaction of these cells with the surrounding stroma. 38 Notably, our studies demonstrate that the genetic content of the epithelial tumor cells modulates the architecture of the tumor microenvironment. The impact that these changes in the stroma had on tumor development will require further systematic analysis. We propose that the defective recruitment of immune cells may allow emerging tumors that lack p53 and av to evade immune surveillance. This mechanism may have important clinical implications because the well-documented high risk of SCCs in immunosuppressed patients implies that immune surveillance is a p53 and av cooperate during SCC development A Savar et al primary mechanism of defense against SCC development. 2,3 Our findings suggest that epithelial cells that lack av and p53 expression evade the anticancer immune response by limiting the presence of immune cells in the environment of nascent tumors. The defective angiogenesis observed in these tumors is likely to have a significant role in this process.
However, as SCCs increase in size, a deficient vasculature may restrain tumor growth by limiting their supply of nutrients. In addition, although the immune system protects against SCC development, infiltrating immune cells can also promote tumor progression, and so do CAFs. 38, 39 We speculate that deficits in vasculature and cellular components of the stroma in av À /p53 À SCCs pose a barrier to tumor growth that may explain why av À / p53 À tumors grew significantly slower than tumors that expressed av or p53. The lack of a supportive stroma may also be why the av À /p53 À tumors did not metastasize, despite how rapidly they formed. However, metastasis rates were also low for tumors that expressed either av or p53, which contained a more robust stroma than av À /p53 À SCCs. How the changes in the microenvironment induced by epithelial av and p53 contribute to metastasis will have to be determined in mouse models prone to metastasis. 12 In summary, we have shown that codeletion of the p53 and av genes in stratified epithelia promoted the rapid development of SCCs, which were characterized by slow growth and a markedly defective microenvironment. The accelerated tumor development induced by loss of epithelial p53 and av may be promoted by both Akt activation, which blocks anoikis, and the defective recruitment of immune cells, which allows epithelial tumor cells to escape from immune surveillance. The slow growth of av À /p53 À SCCs is also consistent with a primary contribution of the stroma to the tumor development because the defective angiogenesis may limit the nutrient supply required to sustain tumor growth, and the lack of protumorigenic stromal cells may prevent tumor progression. Finally, our findings may help improve therapies to treat SCC carcinomas that carry p53 mutations using a combination of inhibitors of av integrin and Akt.
MATERIALS AND METHODS

Mouse models
Mice carrying the K14.CrePR1 transgene and conditional alleles for av and p53 have been described previously. 11, 26, 40 Mouse genotyping and analysis of the activation of conditional alleles (Supplementary Figure S6) was performed by polymerase chain reaction as described previously. 11, 25, 40, 41 Mice with excessive tumor burden as per The University of Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee (IACUC) guidelines were euthanized, their tumors were harvested and their thoracic and abdominal cavities were assessed for evidence of metastasis. Tumor development was represented using Kaplan-Meier curves, and the log-rank test was used to assess differences between groups. P-values o0.05 were considered statistically significant. All comparative studies were conducted using littermates with the indicated genotypes. Overall, research involving mice was performed in compliance with the IACUC guidelines.
Histologic and immunohistochemical analysis
Tumors were fixed in 10% neutral-buffered formalin. Samples were then transferred to 75% ethanol and embedded in paraffin. Histologic sections were stained with hematoxylin and eosin or processed for immunohistochemical analysis. Tissue sections used for immunohistochemical analysis were deparaffinized and then rehydrated following xylene and alcohol series. Antigen retrieval was performed in 100 mM sodium citrate (pH 6.0), and endogenous peroxidase was blocked with 1% hydrogen peroxide. Then, tissue sections were incubated with primary antibodies for p-Akt (Epitomics, Burlingame, CA, USA); p-Erk and p-Smad2 (Cell Signaling Technology, Danvers, MA, USA); CD45, Gr-1, F4/80 and Nk1 (BioLegend, San Diego, CA, USA); CD3, a À SMA and Ki-67 (Thermo Scientific, Rockford, IL, USA); and p16 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies were detected using the ImmPRESS system (Vector Laboratories, Burlingame, CA, USA). Slides were visualized on a Leica DMLA microscope (Leica Microsystems, Buffalo Grove, IL, USA), and images were captured with a Hamamatsu ORCA-ER camera (Hamamatsu, Shizuoka, Japan).
Western blot analysis
Total lysates were generated by solubilizing tumors in Laemmli protein loading buffer and heating at 100 1C for 10 min. An equal amount of proteins from each sample was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and the gels were transferred onto Hybond-P membranes (GE Healthcare Life Sciences, Piscataway, NJ, USA). Membranes were incubated with the antibodies for p-Smad2, Smad2/3, p-Akt, total-Akt, p-Erk, total-Erk, p-STAT3 and total-STAT3 from Cell Signaling Technology; p-Smad3 (Epitomics) and actin (Santa Cruz Biotechnology). Signal was detected by incubating the membranes with secondary antibodies labeled with horseradish peroxidase and revealed with the ECL Plus detection system (GE Healthcare Life Sciences).
Analysis of the tumor vasculature
Tumors were double-stained with CD31 (BioLegend) and K14 (Covance, Princeton, NJ, USA) antibodies. Briefly, harvested tumors were embedded in OCT, frozen on dry ice, sectioned and stored at À 80 1C until used. Tumor sections were fixed in 75% acetone/25% ethanol at À 20 1C for 15 min, blocked with 5% bovine serum albumin for 30 min and incubated with primary antibodies. The slides were then washed two times with phosphate-buffered saline-0.1% Tween, two times with phosphatebuffered saline and finally rinsed three times with dH 2 O. Then, tumor sections were incubated with 1 mg/ml bovine serum albumin in phosphate-buffered saline for 15 min followed by secondary antibodies labeled with Alexa Fluor 594 or Alexa Fluor 488 (Life Technologies, Grand Island, NY, USA) for 1 h. Slides were then washed as indicated above, rinsed with 100% ethanol and mounted with VECTASHIELD (Vector Laboratories).
The immunofluorescence signal was visualized on an Olympus IX71 fluorescence microscope (Olympus, Center Valley, PA, USA), and images were captured using a Hamamatsu ORCA-ER camera (Hamamatsu) and processed with Photoshop CS5 (Adobe, San Jose, CA, USA). The microvessel area was determined in representative images of the different tumors in which the number of pixels occupied by vessels was computed in Photoshop and transformed into the surface area. At least four images per tumor were analyzed in all studies.
Statistical analysis
All groups were compared using the two-tailed Student's t-test. Error bars represent the mean±s.e.m. P-values o0.05 were considered statistically significant.
